阿斯利康胃癌疗法获美国FDA授予优先审评资格

格隆汇
Nov 19
阿斯利康宣布,美国食品药品监督管理局(FDA)已受理其胃癌疗法sonesitatug vedotin(Sone-Ve)的上市申请,并授予优先审评资格。阿斯利康提交的生物制品许可申请旨在寻求美国批准这款抗体偶联药物作为胃癌、胃食管结合部癌(GEJ)或食管腺癌(EAC)的后线治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10